Frankfurt / Main (dpa) – The German stock market heads into the weekend with a friendly trend. The momentum is limited. The Dax was trading 0.25 percent higher in the afternoon at 13,119.48 points.
This indicates a weekly gain of about 0.3 percent for the leading index. The MDax of the 60 midsize stocks rose 0.34 percent on Friday to 28,842.80 meters. The leading euro zone index, EuroStoxx 50, rose about 0.3 percent.
Investors are divided between concerns about the effects of large numbers of coronaviruses and the hope that several vaccines against the virus will be available soon. “Investors want more than vaccine success stories. The theoretical and practical benefits are currently being weighed on the gold balance, ”commented market expert Timo Emden of Emden Research.
From a company perspective, the news situation is quite weak. The agenda shows that the corporate reporting season is almost over. Shares of Thyssenkrupp, CTS Eventim and Kion partially revised the losses of the previous day and were among the strongest MDax values with increases of between 2.4 and 4.7 percent. Thyssenkrupp showed the most momentum. In the industrial group, attention is now increasingly focused on the future of the heavy-loss steel division, in which the British group Liberty Steel has shown interest.
Investors’ attention turned to Biontech stocks with the upcoming US registration application for the corona vaccine developed with Pfizer. Both companies announced that an emergency approval request will be submitted to the US FDA on Friday.In premarket trading in the United States, Biontech shares, which are traded primarily in New York, advanced 6, 6 percent.
Freenet shares rose 1.1 percent after the mobile operator’s debt reduction announcement. The loan to finance the share package acquired in 2016 from Sunrise for an amount of 610 million euros will be repaid this Friday, Freenet reported. With the complete sale of around 11 million Sunrise shares, Freenet recently received around € 1.1 billion.
Paion newspapers were up 5.3 percent. The Aachen-based biopharmaceutical company submitted positive study data for the planned EU approval of the anesthetic remimazolam. The drug had already received approval for the US market in July.
The euro was last traded at $ 1.1861. The European Central Bank had set the reference rate the day before at $ 1.1832. The current yield in the bond market stagnated at minus 0.58 percent. The Rex bond index rose 0.01 percent to 146.05 points. The Bund futures gained 0.10 percent to 175.50 points in the early afternoon.